10-Q · May 15, 2026
Advanced Biomed (ADVB) experienced a notable decrease in losses for the three-month period ending March 31, 2026, reporting a net loss of $489,000 compared to a loss of $1.38 million for the same period in the prior…
Earnings analysis · 10-K
ADVB earnings analysis
Filed October 13, 2026 · Our reading of the company's report
The latest report
Advanced Biomed completed a fundamental transition from biotechnology to FinTruth-focused enterprise AI, producing $127,637 of initial revenue after acquiring Acellent, but the revenue was agency-fee based and the…
Read full summary
Advanced Biomed completed a fundamental transition from biotechnology to FinTruth-focused enterprise AI, producing $127,637 of initial revenue after acquiring Acellent, but the revenue was agency-fee based and the company had no FinTruth customer revenue as of the report date. Fiscal 2026 headline profitability and EPS were driven by a $14.015 million disposal gain, while continuing operations generated a $6.261 million net loss and ended with only $385,535 of cash. The strategy offers substantial potential if commercial adoption develops, but limited operating history, concentrated receivables, financing needs and material internal-control weaknesses make the near-term outlook high risk.
Reported figures
- Earnings per share
- $5.33
- Segment
- Continuing operations: one reportable technology and software segment; revenue was $127,637 in fiscal 2026 versus $0 in fiscal 2025. Historical biotechnology operations are presented as discontinued operations.
What stood out
-
Pivot to FinTruth AI
The company executed a major strategic pivot: it disposed of its Hong Kong biotechnology subsidiary on December 31, 2025 and its Taiwan subsidiary on June 30, 2026, then acquired Acellent in April 2026 to focus on FinTruth and enterprise AI applications.
-
Initial AI monetization achieved
Continuing-operations revenue increased from $0 in fiscal 2025 to $127,637 in fiscal 2026, but the revenue consisted of one-off agency services rather than recurring FinTruth customer revenue. Acellent contributed $127,637 of revenue and incurred a consolidated net loss of $13,406 during the partial post-acquisition period.
-
Headline EPS boosted by disposals
Reported diluted EPS improved to $5.33 from $(3.18), primarily because the company recognized a $14.015 million gain on disposal of subsidiaries. Continuing operations remained loss-making, with a diluted loss per share of $(5.00) in fiscal 2026.
-
Continuing cash burn moderated
Operating cash use from continuing operations declined to $961,341 from $2.308 million in fiscal 2025. However, fiscal 2026 also included $2.582 million of continuing-operations investing cash outflow and ended with only $385,535 of cash.
-
IPO proceeds funded AI transition
The company used approximately $3.60 million of its $5.60 million IPO net proceeds by June 30, 2026, with approximately 70% allocated to research and development, 10% to marketing and promotion, and 20% to working capital.
-
Capital retained for expansion
Capital allocation was directed toward restructuring and the Acellent acquisition rather than shareholder returns: Acellent was acquired for an estimated $1.080 million of consideration, including 270,000 shares, and the company has never paid cash dividends or made share repurchases.
What to watch
-
Unproven FinTruth commercialization
The new AI strategy has limited evidence of commercial traction: the filing states that FinTruth had generated no customer revenue as of the report date and that the $127,637 of continuing-operations revenue was derived from agency fees. The company must convert pilots and proof-of-concept engagements into recurring enterprise contracts.
-
Receivables and financing dependency
Liquidity is concentrated in receivables rather than cash. At June 30, 2026, cash was $385,535, while $12,959,826 was due from former subsidiaries; the company recorded a $2,918,909 expected-credit-loss provision and states that collection timing is significant to liquidity.
-
Material weaknesses in controls
The company reported ineffective internal control over financial reporting as of June 30, 2026, citing insufficiently trained finance personnel, inadequate U.S. GAAP policies, an improper approval mechanism and inadequate periodic user-access reviews. This is particularly material as the company transitions businesses and reported $6,261,276 of continuing-operations net loss.
Management's outlook
The 10-K provides no quantitative annual outlook. Management states that future results will depend on commercialization of FinTruth, customer expansion, recurring revenue generation and control of operating costs.
Earlier filings 1
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.